Recent Australian trends indicate that shave biopsies for diagnosing lesions suspicious of melanoma are increasing, yet reasons for this remain relatively unknown. We sought to understand which ...

In one analysis, 16% of men with no suspicious lesions on MRI had clinically significant prostate cancer identified after ...

Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.

ScreenPoint Medical today announced the acquisition of Biomediq A/S, a research-based company focused on the research, ...

Boston Scientific Corporation (NYSE:BSX) agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy ...

Calcipotriol-plus–5-FU therapy activates immune pathways, offering long-lasting protection against squamous cell carcinoma by ...

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.

Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular lithotripsy (IVL) platform developer ...

Cervical cancer remains a major health threat for women globally, with the highest incidence in developing nations. Despite ...

Patrick Wood, an analyst from Morgan Stanley, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price ...

The regenerative medicine company disappointed its shareholders with a revenue miss that has dragged down full-year results ...